Prostate Cancer Coverage from Every Angle

Nicholas D. James, PhD, MBBS, on Clinical Implications of STAMPEDE Trial Results: Abiraterone Acetate Plus Prednisolone in Prostate Cancer

Posted: Wednesday, September 23, 2020

Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses how the long-term STAMPEDE findings on abiraterone acetate plus prednisolone, which showed benefits in terms of survival and toxicity, fit into evolving clinical practice.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.